<html>
<head>PUBMED IDs for HMGN5</head>
<body bgcolor='#C5F0F2'><h1>HMGN5</h1><a href='https://pubmed.ncbi.nlm.nih.gov/20123071/'>HMGN5/NSBP1: a new member of the HMGN protein family that affects chromatin structure and function.</a> April 22  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/21373965/'>HMGN5: a potential oncogene in gliomas.</a> January 10  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/21518955/'>Distinct properties of human HMGN5 reveal a rapidly evolving but functionally conserved nucleosome binding protein.</a> August 24  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/22504871/'>Small interfering RNA targeting HMGN5 induces apoptosis via modulation of a mitochondrial pathway and Bcl-2 family proteins in prostate cancer cells.</a> September 21  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/22994738/'>Knockdown of HMGN5 expression by RNA interference induces cell cycle arrest in human lung cancer cells.</a> June 5  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/22994734/'>Effects of multiple-target anti-microRNA antisense oligodeoxyribonucleotides on proliferation and migration of gastric cancer cells.</a> June 5  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/24664583/'>High-mobility group nucleosome-binding domain 5 increases drug resistance in osteosarcoma through upregulating autophagy.</a> October 7  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/24687550/'>The expression and clinical significance of high mobility group nucleosome binding domain 5 in human osteosarcoma.</a> October 7  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25307178/'>HMGN5 knockdown sensitizes prostate cancer cells to ionizing radiation.</a> February 6  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25315189/'>The high-mobility group nucleosome-binding domain 5 is highly expressed in breast cancer and promotes the proliferation and invasion of breast cancer cells.</a> June 13  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/25530340/'>Nucleosome-binding protein HMGN2 exhibits antitumor activity in human SaO2 and U2-OS osteosarcoma cell lines.</a> November 18  2014<br><a href='https://pubmed.ncbi.nlm.nih.gov/26394192/'>microRNA-340 Suppresses Tumorigenic Potential of Prostate Cancer Cells by Targeting High-Mobility Group Nucleosome-Binding Domain 5.</a> May 25  2015<br></body></html>
